Rymuza, J., Popow, M., Żurecka, Z., Przedlacki, J., Bednarczuk, T., & Miśkiewicz, P. (2018). Therapy of moderate-to-severe Graves’ orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density. Endocrine.

Rymuza, Joanna, Michał Popow, Zuzanna Żurecka, Jerzy Przedlacki, Tomasz Bednarczuk, and Piotr Miśkiewicz. "Therapy of Moderate-to-severe Graves’ Orbitopathy With Intravenous Methylprednisolone Pulses Is Not Associated With Loss of Bone Mineral Density." Endocrine 2018.

Rymuza, Joanna, et al. "Therapy of Moderate-to-severe Graves’ Orbitopathy With Intravenous Methylprednisolone Pulses Is Not Associated With Loss of Bone Mineral Density." Endocrine 2018.